Cytokinetics EVP Sells Over $100K in Stock

Andrew Callos, executive vice president at Cytokinetics, sold 1,709 shares of the company's stock.

Mar. 17, 2026 at 9:58am

Got story updates? Submit your updates here. ›

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 1,709 shares of the company's stock on Monday, March 16th. The shares were sold at an average price of $61.03, resulting in a total transaction of $104,300.27. Following the sale, Callos still owns 46,149 shares in the company, valued at $2,816,473.47.

Why it matters

Insider transactions, such as stock sales by company executives, can provide insights into management's views on the company's prospects. Callos' sale represents a 3.57% decrease in his position, which may signal his belief that the stock is overvalued or that he needs to diversify his holdings.

The details

Callos sold the 1,709 shares through an open market transaction. The sale was disclosed in a filing with the Securities and Exchange Commission. Cytokinetics is a late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

  • The shares were sold on Monday, March 16th, 2026.

The players

Andrew Callos

Executive Vice President at Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

The takeaway

This insider sale by a Cytokinetics executive may signal the company's stock is overvalued or that the executive is looking to diversify his holdings, though the reasons behind the sale are not explicitly stated. Investors should continue to monitor Cytokinetics' financial performance and any further insider transactions.